Source 1primary paper2026MED
Toolkit/dual-receptor lateral flow biosensor
dual-receptor lateral flow biosensor
Also known as: dual-mode point-of-care testing platform, LFB
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We report a novel dual-receptor lateral flow biosensor (LFB) for the rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells (CTCs).
Usefulness & Problems
Why this is useful
This lateral flow biosensor detects MCF-7 breast cancer cells using dual recognition on a strip. It forms an aptamer-cell-antibody sandwich complex and produces a visual signal within minutes.; rapid visual detection of MCF-7 breast cancer cells; point-of-care screening for circulating tumor cell model samples; optional strip-reader-based quantification
Source:
This lateral flow biosensor detects MCF-7 breast cancer cells using dual recognition on a strip. It forms an aptamer-cell-antibody sandwich complex and produces a visual signal within minutes.
Source:
rapid visual detection of MCF-7 breast cancer cells
Source:
point-of-care screening for circulating tumor cell model samples
Source:
optional strip-reader-based quantification
Problem solved
It addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.; provides instrument-free visual detection of target cells within minutes; combines aptamer-based detection with antibody-based capture in a sandwich-format strip assay
Source:
It addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.
Source:
provides instrument-free visual detection of target cells within minutes
Source:
combines aptamer-based detection with antibody-based capture in a sandwich-format strip assay
Problem links
combines aptamer-based detection with antibody-based capture in a sandwich-format strip assay
LiteratureIt addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.
Source:
It addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.
provides instrument-free visual detection of target cells within minutes
LiteratureIt addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.
Source:
It addresses the need for rapid, sensitive, and simple detection of breast-cancer-cell models for circulating tumor cell screening. The platform is positioned as a cost-effective point-of-care format.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Mechanisms
affinity-based molecular recognitioncolloidal gold colorimetric reportinglateral flow capturesandwich complex formationTarget processes
recombinationselectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
The assay requires a MUC1-specific aptamer linked to colloidal gold nanoparticles and an anti-MUC1 antibody immobilized on the test line. Optional quantification uses a strip reader.; requires a MUC1-specific aptamer conjugated to colloidal gold nanoparticles; requires an anti-MUC1 antibody immobilized at the test line; depends on MUC1-mediated target recognition
The abstract does not show that the platform fully validates clinical circulating tumor cell detection in patient samples. It also does not specify broader cross-cell-type specificity or exact reagent identities.; abstract only reports MCF-7 cells as a model for circulating tumor cells; exact aptamer identity and antibody clone are not specified in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The assay shows robust performance in spiked human blood samples and has potential as a simple, cost-effective dual-mode point-of-care testing platform for early detection and monitoring of breast cancer circulating tumor cells.
The assay also demonstrates robust performance in spiked human blood samples, highlighting its potential as a simple, cost-effective dual-mode point-of-care testing (POCT) platform. This platform supports both rapid visual screening and optional strip-reader-based quantification, making it suitable for early detection and monitoring of breast cancer CTCs.
The biosensor uses a MUC1-specific aptamer on colloidal gold nanoparticles as the detection probe and an anti-MUC1 antibody at the test line as the capture probe to form an aptamer-cell-antibody sandwich complex upon target recognition.
The biosensor employs a MUC1-specific aptamer conjugated to colloidal gold nanoparticles as the detection probe and an anti-MUC1 antibody immobilized at the test line as the capture probe, forming a unique "aptamer-cell-antibody" sandwich complex upon target recognition.
The dual-receptor lateral flow biosensor achieves a detection limit of 675 cells and provides instrument-free visual readout within minutes.
This design enables instrument-free, visual readout within minutes, achieving a detection limit of 675 cells.
detection limit 675 cellstime to readout within minutes
A dual-receptor lateral flow biosensor enables rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells.
We report a novel dual-receptor lateral flow biosensor (LFB) for the rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells (CTCs).
Approval Evidence
1 source4 linked approval claimsfirst-pass slug dual-receptor-lateral-flow-biosensor
We report a novel dual-receptor lateral flow biosensor (LFB) for the rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells (CTCs).
Source:
application contextsupports
The assay shows robust performance in spiked human blood samples and has potential as a simple, cost-effective dual-mode point-of-care testing platform for early detection and monitoring of breast cancer circulating tumor cells.
The assay also demonstrates robust performance in spiked human blood samples, highlighting its potential as a simple, cost-effective dual-mode point-of-care testing (POCT) platform. This platform supports both rapid visual screening and optional strip-reader-based quantification, making it suitable for early detection and monitoring of breast cancer CTCs.
Source:
mechanism of actionsupports
The biosensor uses a MUC1-specific aptamer on colloidal gold nanoparticles as the detection probe and an anti-MUC1 antibody at the test line as the capture probe to form an aptamer-cell-antibody sandwich complex upon target recognition.
The biosensor employs a MUC1-specific aptamer conjugated to colloidal gold nanoparticles as the detection probe and an anti-MUC1 antibody immobilized at the test line as the capture probe, forming a unique "aptamer-cell-antibody" sandwich complex upon target recognition.
Source:
performancesupports
The dual-receptor lateral flow biosensor achieves a detection limit of 675 cells and provides instrument-free visual readout within minutes.
This design enables instrument-free, visual readout within minutes, achieving a detection limit of 675 cells.
Source:
tool capabilitysupports
A dual-receptor lateral flow biosensor enables rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells.
We report a novel dual-receptor lateral flow biosensor (LFB) for the rapid, sensitive, and visual detection of MCF-7 breast cancer cells as a model for circulating tumor cells (CTCs).
Source:
Comparisons
Source-stated alternatives
The abstract contrasts rapid visual screening with optional strip-reader-based quantification as two operating modes of the same platform. No separate competing assay platform is explicitly named in the abstract.
Source:
The abstract contrasts rapid visual screening with optional strip-reader-based quantification as two operating modes of the same platform. No separate competing assay platform is explicitly named in the abstract.
Source-backed strengths
rapid visual readout within minutes; instrument-free screening mode; cost-effective point-of-care potential; works in spiked human blood samples; supports both visual screening and reader-based quantification
Source:
rapid visual readout within minutes
Source:
instrument-free screening mode
Source:
cost-effective point-of-care potential
Source:
works in spiked human blood samples
Source:
supports both visual screening and reader-based quantification
Compared with haematoxylin-eosin stained histological sections
dual-receptor lateral flow biosensor and haematoxylin-eosin stained histological sections address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Compared with open-source microplate reader
dual-receptor lateral flow biosensor and open-source microplate reader address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Strengths here: looks easier to implement in practice.
Compared with touchscreen-equipped operant conditioning chambers
dual-receptor lateral flow biosensor and touchscreen-equipped operant conditioning chambers address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Ranked Citations
- 1.